Crescent Biopharma, Inc. CBIO
13.00 USD +0.09 (+0.70%)
Regular-session close
13.00 0.00 0.00%
After hours · Nov 20, 4:01 PM ET
12.53 Day range 13.30
8.72 52-week range 27.41
- YTD
- +9.61%
- 1 year
- -0.61%
5D -1.75 (-12.37%)
- Market cap
- 543.21M
- EPS (ttm)
- -7.29
- Shares out
- 37.98M
- Forward P/E
- -17.04
- Dividend
- 15.94 (792.92%)
- Ex-dividend date
- Jan 13, 2023
- YTD return
- +9.61%
- 1-year return
- -0.61%
- Volume
- 422.37K
- Avg volume
- 357.98K
- Open
- 12.55
- Previous close
- 12.91
- Day's range
- 12.53 – 13.30
- 52-week range
- 8.72 – 27.41
- Beta
- 1.29
- Analysts
- Hold
Key statistics
- 50-day average
- 0.638078
- 200-day average
- 0.365086
- Enterprise value
- 50.50M
- Free cash flow
- -3.02M
- Total cash
- 2.23M
- Return on equity
- -269.01%
- Short % of float
- 0.11%
Fundamental scorecard
7 of 25 checks passed on CBIO’s reported financials
7of 25 checks passed
- Value 2 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
CBIO Revenue — quarterly 3.12M
CBIO Net income — quarterly -37.73M
CBIO EPS — quarterly -0.90
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 26, 2023 | Sep 1, 2023 | -0.05 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | -0.07 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 30, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 15, 2022 | Jun 1, 2022 | -0.22 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2021 | Raymond James | down | Outperform | Market Perform |
| Aug 5, 2021 | Raymond James | main | — | Outperform |
| Apr 28, 2021 | Raymond James | main | — | Outperform |
| Feb 9, 2021 | Piper Sandler | init | — | Overweight |
| Feb 3, 2021 | Raymond James | main | — | Outperform |
| Jan 3, 2019 | Oppenheimer | init | — | Outperform |
About Crescent Biopharma, Inc.
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- catalystbiosciences.com
News
Your note
Sign in to keep a note on CBIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HUNT ANDREA | Director | Stock Award(Grant) | Jan 6, 2022 | 28,228 |
| LING GEOFFREY M. D. | Director | Stock Award(Grant) | Jan 6, 2022 | 31,790 |
| WILLIAMS EDDIE | Director | Stock Award(Grant) | Jan 6, 2022 | 34,804 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 2.04% | 774,386 | 272.27K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.71% | 270,033 | 94.94K | Jun 29, 2023 |
| Blackrock Inc. | 0.40% | 153,657 | 54.02K | Jun 29, 2023 |
| Acadian Asset Management. LLC | 0.38% | 144,028 | 50.64K | Jun 29, 2023 |
| Kynam Capital Management, LP | 0.24% | 89,886 | 31.60K | Jun 29, 2023 |
| Northern Trust Corporation | 0.23% | 86,412 | 30.38K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.42% | 160,399 | 35.29K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.09% | 34,507 | 7.59K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.09% | 35,667 | 7.85K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.07% | 25,124 | 5.53K | May 30, 2023 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.02% | 7,752 | 4.34K | Aug 30, 2023 |
